Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martina Menacher

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
BMC Neurology|September 24, 2020
Alemtuzumab-associated diffuse alveolar damage - a case reportAntonios Bayas, Martina Menacher, Martin Schwaiblmair, et al.
Therapeutic Advances in Neurological Disorders|December 30, 2024
Complement inhibition in seropositive generalized myasthenia gravis as rescue therapy in impending and effective treatment in frequently recurring impending myasthenic crisis-a case seriesMartina Menacher, Monika Ellssel, Isabelle Kwiedor, et al.
Therapeutic Advances in Neurological Disorders|December 30, 2024
First line treatment with subcutaneous efgartigimod in impending myasthenic crisis: a case reportIsabelle Kwiedor, Martina Menacher, Monika Ellßel, et al.
Lancet (London, England)|April 17, 2021
Bilateral superior ophthalmic vein thrombosis, ischaemic stroke, and immune thrombocytopenia after ChAdOx1 nCoV-19 vaccinationAntonios Bayas, Martina Menacher, Monika Christ, et al.
Lancet (London, England)|February 17, 2024
<sup>18</sup>fluorodeoxyglucose PET/CT as possible early diagnostic tool preceding MRI changes in Borna disease virus 1 encephalitisAntonios Bayas, Martina Menacher, Constantin Lapa, et al.
Kidney International|October 19, 2017
Aprotinin prevents proteolytic epithelial sodium channel (ENaC) activation and volume retention in nephrotic syndromeBernhard N Bohnert, Martina Menacher, Andrea Janessa, et al.
Neurological Research and Practice|November 6, 2022
Real-world evidence on siponimod treatment in patients with secondary progressive multiple sclerosisLiesa Regner-Nelke, Marc Pawlitzki, Alice Willison, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
BMC Neurology|September 24, 2020
Alemtuzumab-associated diffuse alveolar damage - a case reportAntonios Bayas, Martina Menacher, Martin Schwaiblmair, et al.
Therapeutic Advances in Neurological Disorders|December 30, 2024
Complement inhibition in seropositive generalized myasthenia gravis as rescue therapy in impending and effective treatment in frequently recurring impending myasthenic crisis-a case seriesMartina Menacher, Monika Ellssel, Isabelle Kwiedor, et al.
Therapeutic Advances in Neurological Disorders|December 30, 2024
First line treatment with subcutaneous efgartigimod in impending myasthenic crisis: a case reportIsabelle Kwiedor, Martina Menacher, Monika Ellßel, et al.
Lancet (London, England)|April 17, 2021
Bilateral superior ophthalmic vein thrombosis, ischaemic stroke, and immune thrombocytopenia after ChAdOx1 nCoV-19 vaccinationAntonios Bayas, Martina Menacher, Monika Christ, et al.
Lancet (London, England)|February 17, 2024
<sup>18</sup>fluorodeoxyglucose PET/CT as possible early diagnostic tool preceding MRI changes in Borna disease virus 1 encephalitisAntonios Bayas, Martina Menacher, Constantin Lapa, et al.
Kidney International|October 19, 2017
Aprotinin prevents proteolytic epithelial sodium channel (ENaC) activation and volume retention in nephrotic syndromeBernhard N Bohnert, Martina Menacher, Andrea Janessa, et al.
Neurological Research and Practice|November 6, 2022
Real-world evidence on siponimod treatment in patients with secondary progressive multiple sclerosisLiesa Regner-Nelke, Marc Pawlitzki, Alice Willison, et al.
Pageof 1